Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Stryker is extending its acquisition-led expansion strategy into another fast-growing corner of orthopaedics.</li><li>On August 31, 2026, the company signed a definitive agreement to acquire privately held ZuriMED, developer of the commercialized FiberLocker System, a soft-tissue augmentation technology designed to improve biomechanical strength in rotator cuff repair.</li><li>The transaction remains subject to customary closing conditions, with both companies continuing to operate independently until completion.</li></ul>

Stryker is extending its acquisition-led expansion strategy into another fast-growing corner of orthopaedics.On August 31, 2026, the company signed a definitive agreement to acquire privately held ZuriMED, developer of the commercialized FiberLocker System, a soft-tissue augmentation technology designed to improve biomechanical strength in rotator cuff repair.The transaction remains subject to customary closing conditions, with both companies continuing to operate independently until completion.

Stryker ZuriMED Acquisition: The Next Big Growth Driver In Orthopaedics?

<ul><li>Stryker Corporation reported second quarter 2026 results that reflected a broad-based recovery and resilient demand across its diversified medical technology portfolio despite earlier operational challenges.</li><li>The company posted 9% organic sales growth, driven by strong performances in both its MedSurg and Neurotechnology and Orthopaedics segments.</li><li>Geographically, U.S. organic growth was 9%, with double-digit growth in Medical, Trauma & Extremities, and Endoscopy businesses, partially offset by supply disruptions in the Peripheral Vascular segment that caused significant backorders and lost sales during the quarter.</li></ul>

Stryker Corporation reported second quarter 2026 results that reflected a broad-based recovery and resilient demand across its diversified medical technology portfolio despite earlier operational challenges.The company posted 9% organic sales growth, driven by strong performances in both its MedSurg and Neurotechnology and Orthopaedics segments.Geographically, U.S. organic growth was 9%, with double-digit growth in Medical, Trauma & Extremities, and Endoscopy businesses, partially offset by supply disruptions in the Peripheral Vascular segment that caused significant backorders and lost sales during the quarter.

Stryker Corporation’s Hidden Growth Engine — Mako Utilization Keeps Reaching New Highs!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Stryker is a leading global medical technology company with a strong, diversified portfolio across MedSurg, Neurotechnology, and Orthopaedics, consistently driving growth through innovation and strategic acquisitions.</li>
  <li>The company's Mako SmartRobotics platform provides a significant competitive advantage and market leadership in robotic-assisted surgery, particularly in hip and knee replacements, which is a key long-term growth driver.</li>
  <li>While demonstrating financial resilience and consistent dividend growth, the company faces risks related to cybersecurity vulnerabilities, successful integration of acquisitions, and navigating a complex and competitive regulatory landscape.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Stryker is a leading global medical technology company with a strong, diversified portfolio across MedSurg, Neurotechnology, and Orthopaedics, consistently driving growth through innovation and strategic acquisitions.
  The company's Mako SmartRobotics platform provides a significant competitive advantage and market leadership in robotic-assisted surgery, particularly in hip and knee replacements, which is a key long-term growth driver.
  While demonstrating financial resilience and consistent dividend growth, the company faces risks related to cybersecurity vulnerabilities, successful integration of acquisitions, and navigating a complex and competitive regulatory landscape.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a> reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.</li>
<li>The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.</li>
<li>In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.</li>
</ul>



Medtronic Plc (MDT US) reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.
The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.
In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.


Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

<ul><li>Stryker Corporation is moving deeper into the peripheral vascular market through its planned acquisition of Amplitude Vascular Systems for up to $835 million, adding a next-generation hydraulic intravascular lithotripsy platform designed to treat calcified peripheral arterial disease.</li><li>The deal comes at a notable moment for Stryker, which recently reported a disrupted Q1 2026 due to a cyber incident but maintained full-year guidance, citing healthy procedure volumes, strong capital demand, and confidence in sales recovery through the remainder of the year.</li><li>Management also described the AVS transaction as a step toward expanding treatment options for peripheral vascular customers and broadening Stryker’s presence in cardiovascular care.</li></ul>

Stryker Corporation is moving deeper into the peripheral vascular market through its planned acquisition of Amplitude Vascular Systems for up to $835 million, adding a next-generation hydraulic intravascular lithotripsy platform designed to treat calcified peripheral arterial disease.The deal comes at a notable moment for Stryker, which recently reported a disrupted Q1 2026 due to a cyber incident but maintained full-year guidance, citing healthy procedure volumes, strong capital demand, and confidence in sales recovery through the remainder of the year.Management also described the AVS transaction as a step toward expanding treatment options for peripheral vascular customers and broadening Stryker’s presence in cardiovascular care.

Stryker Takeover Play: The $835M Deal That Could Reshape Its Cardiovascular Future!

United States

Stryker Corporation develops, manufactures, and markets specialty surgical and medical products.  The Company's products include implants, biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Stryker Corp (SYK US)

Stryker ZuriMED Acquisition: The Next Big Growth Driver In Orthopaedics?

Stryker is extending its acquisition-led expansion strategy into another fast-growing corner of orthopaedics. On August 31, 2026, the company...

Baptista Research

Stryker Corporation’s Hidden Growth Engine — Mako Utilization Keeps Reaching New Highs!

Stryker Corporation reported second quarter 2026 results that reflected a broad-based recovery and resilient demand across its diversified medical...

Baptista Research

Primer: Stryker Corp (SYK US) - Aug 2026

Stryker is a leading global medical technology company with a strong, diversified portfolio across MedSurg, Neurotechnology, and Orthopaedics,...

αSK Primers

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Stryker Takeover Play: The $835M Deal That Could Reshape Its Cardiovascular Future!

Stryker Corporation is moving deeper into the peripheral vascular market through its planned acquisition of Amplitude Vascular Systems for up to...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Stryker ZuriMED Acquisition: The Next Big Growth Driver In Orthopaedics?

Stryker is extending its acquisition-led expansion strategy into another fast-growing corner of orthopaedics. On August 31, 2026, the company...

Baptista Research

Stryker Corporation’s Hidden Growth Engine — Mako Utilization Keeps Reaching New Highs!

Stryker Corporation reported second quarter 2026 results that reflected a broad-based recovery and resilient demand across its diversified medical...

Baptista Research

Primer: Stryker Corp (SYK US) - Aug 2026

Stryker is a leading global medical technology company with a strong, diversified portfolio across MedSurg, Neurotechnology, and Orthopaedics,...

αSK Primers

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

​Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Stryker Takeover Play: The $835M Deal That Could Reshape Its Cardiovascular Future!

Stryker Corporation is moving deeper into the peripheral vascular market through its planned acquisition of Amplitude Vascular Systems for up to...

Baptista Research

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...